Healiva is a patient-centric Swiss Biotech company delivering personalised, affordable, and innovative therapy combining cell therapies, enzyme technology and medical device for Acute and Chronic wounds.
2-3% of the elderly suffer from venous/arterial ulcers and nearly 25% of diabetics may develop diabetic foot ulcers in their lifetimes. This figure is set to rise with the increasing of contributing factors: diabetes, advanced age and obesity. About ≈60% of chronic wounds remain unhealed. There remains a major gap in the current treatment paradigm leaving society with poor quality of life.
Enzymatic debriding agent: painless, easy-to-use and more effective for wound cleaning and preparation
Epidermal cell graft: personalized treatment for the most severe chronic wounds
Allogenic cell spray: growth factor stimulation with ability to scale to large number of patients
Blood component patch: autologous patch prepared at Point of Care by healthcare professional
Who cares about our innovation?
- Patients will benefit from improved quality of life and reduced pain, eliminating the burden of living with a chronic wound.
- Healthcare providers and hospitals will benefit from increased choice with a novel solution for wound management.
- Healthcare Systems will benefit from more effective alternatives to many of the existing products, carrying the potential for cost reduction.